drugset / Trial / NCT04819412

To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus

NCT04819412

RandomizedParallel-groupSingle-blindPrevention

Summary

Study Rationale A single Rotavirus vaccine container with the vaccine virus and antacid buffer would be ideal for logistical, administrative and distribution ease, especially in routine immunization program. * The advantages of the liquid vaccines are: Liquid vaccines take lesser time to administer compared to the current practice of giving antacid buffer prior to vaccine which takes 40% more time to administer. * Easier to transport as it is stable at 2-80C compared to the frozen formulation that needs to be stored at -200C and transported in dry ice. * Chances of human error during administration are lesser than the sequential administration of antacid and vaccine.

Timeline

Start
2015-03-20
Primary completion
2015-10-30
Completion
2016-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ROTAVAC 5C -F1 Vaccine 105 unknown
Subject ROTAVAC 5C -F2 Vaccine 105 unknown
Comparator ROTAVAC® Vaccine 105 unknown

Indications